2016 ASGCT Annual Metting
May 04, 2016 ‐ May 07, 2016 in Washington, DC
Data on Cellectis' engineered allogeneic CAR T-cell programs will be featured in three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting.
The meeting will be held from May 4 to May 7, 2016 in Washington, DC, USA.
Julianne Smith, Ph.D., Vice President CART Development at Cellectis, to participate in a poster presentation intitled "Allogeneic CAR T-Cells Trageting CD123 Effectively Eliminatre Myeloid Leukemia Cells"
Poster Session: Cancer-Immunotherapy, Cancer Vaccines II
Session Time: Thursday, May 5, 2016, 5:45 PM
Room: Exhibit Hall C & B South
Final abstract number: 397
Philippe Duchateau, Ph.D., Chief Scientific Officer of Cellectis, to participate in a poster presentation intitled "An Engineered CAR T-Cell Platform for Allogeneic Combination Immunotherapy"
Poster Session: Cancer-Targeted Gene and Cell Therapy II
Session Time: Friday, May 6, 2016, 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B South
Final abstract number: 676
Alexandre Juillerat, Ph.D., Senior Scientist at Cellectis, to participate in a poster presentation intitled "Integration of Dual Signal Input Strategies in Novel Chimeric Antigen Receptors to Control the CAR T-Cell Functions"
Poster Session: Cancer-Immunotherapy, Cancer Vaccines III
Session Time: Friday May 6, 2016 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B South
Final abstract number: 651